Biothera has announced that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms. AS1402 is a monoclonal antibody that targets an aberrant form of the cell-surface protein MUC1 that is widely expressed in many types of cancer. Prior to the acquisition, the experimental drug had been in Phase 2 development. Biothera plans to study the combination therapy of Imprime PGG and AS1402 in future cancer trials. The indication has yet to be determined.